-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Vaniprevir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/923590-37-8.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 923590-37-8 |
| Description | Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, and is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes. It has good plasma exposure and excellent liver exposure in multiple species. |
Product Information
| Synonyms | MK7009; MK-7009; MK 7009; Vaniprevir |
| Molecular Weight | 757.94 |
| Molecular Formula | C38H55N5O9S |
| Canonical SMILES | CCC1CC1(C(=O)NS(=O)(=O)C2CC2)NC(=O)C3CC4CN3C(=O)C(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C |
| InChI | InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26+,29-,30+,38+/m0/s1 |
| InChIKey | KUQWGLQLLVFLSM-CXMMALMNSA-N |
| Purity | >98% |
| Density | 1.33g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 1550 |
| Exact Mass | 757.37204952 |
| PSA | 197.59000 |
| Target | HCV; HCV Protease |
| XLogP3-AA | 5.1 |
